Piper Sandler Maintains Overweight on Cogent Biosciences, Raises Price Target to $52
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $39 to $52.
Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overweight and raises the price target from $39 to $52.